Integrated BioPharma market cap is $260.7 m, and annual revenue was $49.98 m in FY 2019

Integrated BioPharma Gross profit (FY, 2019)6.2 M

Integrated BioPharma Gross profit margin (FY, 2019), %12.4%

Integrated BioPharma Net income (FY, 2019)1.7 M

Integrated BioPharma EBIT (FY, 2019)2.7 M

Integrated BioPharma Cash, 30-Jun-2019475 K

Integrated BioPharma revenue was $49.98 m in FY, 2019

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Revenue | 33.7m | 37.5m | 42.2m | 47.0m | 43.7m | 50.0m |

| 11% | 13% | ||||

## Cost of goods sold | 28.8m | 33.1m | 36.7m | 40.3m | 38.7m | 43.8m |

## Gross profit | 4.9m | 4.4m | 5.5m | 6.7m | 5.0m | 6.2m |

| 14% | 12% | 13% | 14% | 11% | 12% |

## General and administrative expense | 3.5m | 3.5m | 3.4m | 3.5m | 3.3m | 3.5m |

## Operating expense total | 3.5m | 3.5m | 3.4m | 3.5m | 3.3m | 3.5m |

## EBIT | 1.4m | 933.0k | 2.1m | 3.2m | 1.7m | 2.7m |

| 4% | 2% | 5% | 7% | 4% | 5% |

## Interest expense | 964.0k | 979.0k | 953.0k | 911.0k | 926.0k | 630.0k |

## Pre tax profit | 220.0k | 869.0k | 1.2m | 1.9m | 1.0m | 2.0m |

## Net Income | 131.0k | 735.0k | 958.0k | 2.3m | 679.0k | 1.7m |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Cash | 451.0k | 71.0k | 395.0k | 132.0k | 228.0k | 475.0k |

## Accounts Receivable | 2.2m | 2.6m | 3.1m | 4.0m | 3.8m | 4.4m |

## Inventories | 5.7m | 5.8m | 7.8m | 7.6m | 7.7m | 8.8m |

## Current Assets | 9.2m | 9.3m | 12.1m | 12.6m | 12.2m | 14.1m |

## PP&E | 1.2m | 1.4m | 1.6m | 1.6m | 1.7m | 1.8m |

## Total Assets | 11.6m | 11.6m | 14.1m | 15.2m | 14.6m | 19.8m |

## Accounts Payable | 5.6m | 5.1m | 5.5m | 4.2m | 4.2m | 3.9m |

## Short-term debt | 588.0k | 719.0k | ||||

## Current Liabilities | 11.7m | 11.9m | 11.8m | 11.2m | 16.2m | 12.4m |

## Long-term debt | ||||||

## Total Debt | 588.0k | 719.0k | ||||

## Total Liabilities | 21.7m | 20.9m | 22.4m | 21.1m | 19.8m | 17.9m |

## Additional Paid-in Capital | 44.6m | 44.7m | 44.7m | 44.8m | 44.8m | 50.2m |

## Retained Earnings | (54.7m) | (53.9m) | (53.0m) | (50.6m) | (50.0m) | (48.3m) |

## Total Equity | (10.2m) | (9.3m) | (8.3m) | (5.9m) | (5.2m) | 1.9m |

## Financial Leverage | -1.1 x | -1.2 x | -1.7 x | -2.6 x | -2.8 x | 10.5 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Net Income | 131.0k | 735.0k | 958.0k | 2.3m | 679.0k | 1.7m |

## Depreciation and Amortization | 390.0k | 405.0k | 351.0k | 393.0k | 348.0k | 321.0k |

## Accounts Receivable | 248.0k | (440.0k) | (527.0k) | (884.0k) | 182.0k | (593.0k) |

## Inventories | 733.0k | (79.0k) | (2.0m) | 111.0k | (96.0k) | (1.1m) |

## Accounts Payable | (247.0k) | (488.0k) | 727.0k | (1.3m) | 7.0k | (329.0k) |

## Cash From Operating Activities | 1.9m | (113.0k) | (594.0k) | 397.0k | 1.2m | 328.0k |

## Purchases of PP&E | (182.0k) | (235.0k) | (109.0k) | (327.0k) | (247.0k) | (414.0k) |

## Cash From Investing Activities | (182.0k) | (156.0k) | (107.0k) | (327.0k) | (242.0k) | (422.0k) |

## Cash From Financing Activities | (1.3m) | (111.0k) | 1.0m | (333.0k) | (830.0k) | 341.0k |

## Interest Paid | 716.0k | 714.0k | 745.0k | 884.0k | 800.0k | 629.0k |

## Income Taxes Paid | 7.0k | 158.0k | 168.0k | 366.0k | 221.0k | 264.0k |

USD | Y, 2019 |
---|---|

## Revenue/Employee | 390.4k |

## Financial Leverage | 10.5 x |